$1.25
2.34% yesterday
Nasdaq, Apr 28, 10:13 pm CET
ISIN
US31189P1021
Symbol
FATE
Sector
Industry

Fate Therapeutics, Inc. Stock price

$1.25
+0.40 47.18% 1M
-1.62 56.45% 6M
-0.40 24.24% YTD
-2.79 69.06% 1Y
-30.40 96.05% 3Y
-26.77 95.54% 5Y
-4.18 76.98% 10Y
Nasdaq, Closing price Mon, Apr 28 2025
-0.03 2.34%
ISIN
US31189P1021
Symbol
FATE
Sector
Industry

Key metrics

Market capitalization $146.69m
Enterprise Value $-47.11m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.38
EV/Sales (TTM) EV/Sales -3.46
P/S ratio (TTM) P/S ratio 10.76
P/B ratio (TTM) P/B ratio 0.46
Revenue growth (TTM) Revenue growth -78.55%
Revenue (TTM) Revenue $13.63m
EBIT (operating result TTM) EBIT $-195.54m
Free Cash Flow (TTM) Free Cash Flow $-123.60m
Cash position $279.07m
EPS (TTM) EPS $-1.65
P/E forward negative
P/S forward 38.34
EV/Sales forward negative
Short interest 15.53%
Show more

Is Fate Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Fate Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Fate Therapeutics, Inc. forecast:

4x Buy
33%
8x Hold
67%

Analyst Opinions

12 Analysts have issued a Fate Therapeutics, Inc. forecast:

Buy
33%
Hold
67%

Financial data from Fate Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
14 14
79% 79%
100%
- Direct Costs 19 19
4% 4%
139%
-5.33 -5.33
112% 112%
-39%
- Selling and Administrative Expenses 55 55
13% 13%
405%
- Research and Development Expense 116 116
25% 25%
851%
-177 -177
3% 3%
-1,296%
- Depreciation and Amortization 19 19
4% 4%
139%
EBIT (Operating Income) EBIT -196 -196
3% 3%
-1,435%
Net Profit -186 -186
16% 16%
-1,367%

In millions USD.

Don't miss a Thing! We will send you all news about Fate Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Fate Therapeutics, Inc. Stock News

Neutral
GlobeNewsWire
15 days ago
–   Recognizes potential of off-the-shelf CAR T-cell therapy to address significant unmet need and enables increased dialogue with FDA throughout the development process
Neutral
GlobeNewsWire
26 days ago
SAN DIEGO, April 02, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on April 1, 2025 the Company granted restricted stock units (RSUs) representi...
Neutral
GlobeNewsWire
about 2 months ago
Phase 1 Dose Expansion Initiated for FT819 Off-the-Shelf CAR T-cell Product Candidate with Fludarabine-free Conditioning in Moderate-to-Severe SLE
More Fate Therapeutics, Inc. News

Company Profile

Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products include immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.

Head office United States
CEO Bahram Valamehr
Employees 181
Founded 2007
Website www.fatetherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today